NNC 0194 0499

Drug Profile

NNC 0194 0499

Alternative Names: NN9499; NNC-0194-0499

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies
  • Mechanism of Action Fibroblast growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 13 Mar 2018 Novo Nordisk initiates a phase I trial in Obesity in USA (SC) (NCT03479892)
  • 26 Oct 2017 Novo Nordisk completes a phase I trial in Obesity in USA (SC) (NCT03015207)
  • 01 Jan 2017 Phase-I clinical trials in Obesity in USA (SC) (NCT03015207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top